Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Qualitative Evaluation of a Complex Intervention to Improve Rheumatic Heart Disease Secondary Prophylaxis

A multifaceted intervention was implemented using quality improvement and chronic care model approaches to improve delivery of penicillin prophylaxis for rheumatic heart disease

Research

SToP (See, Treat, Prevent) skin sores and scabies trial: study protocol for a cluster randomised, stepped-wedge trial for skin disease control in remote Western Australia

Skin infection burden in remote Aboriginal communities can be reduced by the See, Treat, Prevent (SToP skin sores and scabies) trial

Research

Impact of heart disease on maternal, fetal and neonatal outcomes in a low-resource setting

Occult maternal heart disease may be responsible for a substantial proportion of adverse pregnancy outcomes in low-resource settings

Research

Scabies and impetigo in Timor-Leste: A school screening study in two districts

Scabies and impetigo are common in Timor-Leste, with very high prevalence of scabies in the rural district of Ermera

Research

Risk factors for group A streptococcal pharyngitis and skin infections: A case control study

Group A streptococcal (GAS) infections can trigger an immune-mediated response resulting in acute rheumatic fever. The role of social and environmental risk factors for GAS pharyngitis and skin infections are not well understood.

Research

Rheumatic heart disease in Timor-Leste school students: an echocardiography-based prevalence study

The rates of RHD in Timor-Leste are among the highest in the world, and prevalence is higher among girls than boys. Community engagement is essential for ensuring follow-up and the effective delivery of secondary prophylaxis.

Research

Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in Fiji

Young people with screening-detected RHD have worse health outcomes than screen-negative cases in Fiji.

Research

Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community

We report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community.

Research

Attendances during the First 12 Months of Life for Aboriginal Children in Five Remote Communities of Northern Australia

The median number of presentations per child in the first year of life was 21 with multiple reasons for presentation.